| Literature DB >> 33835494 |
Mariángeles Clauzure1,2, Ángel G Valdivieso1, Andrea V Dugour3, Consuelo Mori1, María M Massip-Copiz1, María Á Aguilar1, Verónica Sotomayor1, Cristian J A Asensio1, Juan M Figueroa3, Tomás A Santa-Coloma1.
Abstract
The impairment of the cystic fibrosis transmembrane conductance regulator (CFTR) activity induces intracellular chloride (Cl- ) accumulation. The anion Cl- , acting as a second messenger, stimulates the secretion of interleukin-1β (IL-1β), which starts an autocrine positive feedback loop. Here, we show that NLR family pyrin domain containing 3 (NLRP3) and caspase 1 (CASP1) are indirectly modulated by the intracellular Cl- concentration, showing maximal expression and activity at 75 mM Cl- , in the presence of the ionophores nigericin and tributyltin. The expression of PYD and CARD domain containing (PYCARD/ASC) remained constant from 0 to 125 mM Cl- . The CASP1 inhibitor VX-765 and the NLRP3 inflammasome inhibitor MCC950 completely blocked the Cl- -stimulated IL-1β mRNA expression and partially the IL-1β secretion. DCF fluorescence (cellular reactive oxygen species, cROS) and MitoSOX fluorescence (mitochondrial ROS, mtROS) also showed maximal ROS levels at 75 mM Cl- , a response strongly inhibited by the ROS scavenger N-acetyl-L-cysteine (NAC) or the NADPH oxidase (NOX) inhibitor GKT137831. These inhibitors also affected CASP1 and NLRP3 mRNA and protein expression. More importantly, the serum/glucocorticoid regulated kinase 1 (SGK1) inhibitor GSK650394, or its shRNAs, completely abrogated the IL-1β mRNA response to Cl- and the IL-1β secretion, interrupting the autocrine IL-1β loop. The results suggest that Cl- effects are mediated by SGK1, in which under Cl- modulation stimulates the secretion of mature IL-1β, in turn, responsible for the upregulation of ROS, CASP1, NLRP3 and IL-1β itself, through autocrine signalling.Entities:
Keywords: CFTR; NLRP3; ROS; SGK1; autocrine signalling; chloride anion; chloride channel; inflammasome; interleukin; second messenger
Mesh:
Substances:
Year: 2021 PMID: 33835494 PMCID: PMC8274155 DOI: 10.1111/imm.13336
Source DB: PubMed Journal: Immunology ISSN: 0019-2805 Impact factor: 7.215